Novo Nordisk: partnership with Biocorp
(CercleFinance.com) - Biocorp and Novo Nordisk have announced an agreement to develop and supply a version of Biocorp's Mallya clip-on Bluetooth device for the FlexTouch disposable pen used by diabetic patients.
The terms of the contract remain confidential.
Mallya collects the dose and time of each injection and transfers the information in real time to a mobile application, helping people with diabetes to keep an accurate dose diary.
Biocorp will receive an initial payment followed by various milestone payments. Novo Nordisk plans to distribute Mallya in a number of countries, while Biocorp plans to significantly increase production volumes from 2022.
Copyright (c) 2021 CercleFinance.com. All rights reserved.